22 April 2022
EMA/226804/2022
Press Office

# Start of union reviews

CHMP meeting of 19-22 April 2022

**Table 1. Start of reviews for centrally authorised medicines**

| Name | INN | Type of procedure | Scope |
|---|---|---|---|
| Rubraca | Rucaparib | Article 20 of Regulation (EC) 726/2004 | Procedure triggered by the European Commission asking to CHMP to review the detrimental effect in terms of overall survival seen in a clinical study aiming to confirm the efficacy and safety of Rubraca in the approved '3rd line or more treatment' indication, in the context of all available data, and assess their potential impact on the benefit/risk of Rubraca in that indication. In addition, the EC requested the CHMP to give its opinion, as soon as possible, as to whether temporary |

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

| Name | INN | Type of procedure | Scope |
|---|---|---|---|
| | | | measures are necessary to ensure the safe and effective use of this medicinal product. |